{"id":"NCT02305849","sponsor":"Astellas Pharma Inc","briefTitle":"A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment","officialTitle":"Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-25","primaryCompletion":"2017-06-20","completion":"2017-11-28","firstPosted":"2014-12-03","resultsPosted":"2020-08-03","lastUpdate":"2024-10-28"},"enrollment":519,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Peficitinib","otherNames":["ASP015K"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Peficitinib 100 mg","type":"EXPERIMENTAL"},{"label":"Peficitinib 150 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to MTX","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12","timeFrame":"Baseline and week 12/Early termination (ET)","effectByArm":[{"arm":"Placebo","deltaMin":21.8,"sd":null},{"arm":"Peficitinib 100 mg","deltaMin":58.6,"sd":null},{"arm":"Peficitinib 150 mg","deltaMin":64.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":20},"locations":{"siteCount":146,"countries":["Japan"]},"refs":{"pmids":["35267027","34429152","33929089","33068028","31350269"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=336"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":170},"commonTop":["Nasopharyngitis","Blood creatine phosphokinase increased","Hepatic function abnormal","Pharyngitis","Upper respiratory tract infection"]}}